These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. Reusser P; Gambertoglio JG; Lilleby K; Meyers JD J Infect Dis; 1992 Sep; 166(3):473-9. PubMed ID: 1323614 [TBL] [Abstract][Full Text] [Related]
6. Sensitivity of cytomegalovirus to intravenous foscarnet treatment. Akesson-Johansson A; Lernestedt JO; Ringdén O; Lönnqvist B; Wahren B Bone Marrow Transplant; 1986 Dec; 1(2):215-20. PubMed ID: 2844334 [TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and treatment of cytomegalovirus infections]. Chiba S Nihon Rinsho; 1989 Feb; 47(2):440-5. PubMed ID: 2542666 [No Abstract] [Full Text] [Related]
8. Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. Ganly PS; Arthur C; Goldman JM; Schulenburg WE Postgrad Med J; 1988 May; 64(751):389-91. PubMed ID: 2849092 [TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of cytomegalovirus infections after graft of allogenic bone marrow]. Gluckman E; McMazeron ; Keable H; Meletis J; Bombail D; Jolivet I; Huart JJ; Nebout T; Cavazzana M; De Castro H Nouv Rev Fr Hematol (1978); 1987; 29(1):17-21. PubMed ID: 3035485 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the replication of herpes viruses by phosphonoacetate and related compounds. Newton AA Adv Ophthalmol; 1979; 38():267-75. PubMed ID: 230719 [No Abstract] [Full Text] [Related]
11. [Myelo-meningoradiculitis secondary to cytomegalovirus infection in a non immunocompromised patient. Treatment with foscarnet]. Rogeaux O; Bedos JP; Wolf M; Vachon F Ann Med Interne (Paris); 1992; 143(3):219-20. PubMed ID: 1326248 [No Abstract] [Full Text] [Related]
12. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. Ringdén O; Lönnqvist B; Paulin T; Ahlmén J; Klintmalm G; Wahren B; Lernestedt JO J Antimicrob Chemother; 1986 Mar; 17(3):373-87. PubMed ID: 3009383 [TBL] [Abstract][Full Text] [Related]
13. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Klintmalm G; Lönnqvist B; Oberg B; Gahrton G; Lernestedt JO; Lundgren G; Ringdén O; Robert KH; Wahren B; Groth CG Scand J Infect Dis; 1985; 17(2):157-63. PubMed ID: 2992074 [TBL] [Abstract][Full Text] [Related]
14. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Aschan J; Ringdén O; Ljungman P; Lönnqvist B; Ohlman S Scand J Infect Dis; 1992; 24(2):143-50. PubMed ID: 1322557 [TBL] [Abstract][Full Text] [Related]
15. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation. Ahlmén J; Wijnween AC; Brynger H; Lycke E Scand J Urol Nephrol Suppl; 1985; 92():41-4. PubMed ID: 3008316 [TBL] [Abstract][Full Text] [Related]
16. [Cytomegalovirus infection in patients after lung transplantation]. Cerrina J; Le Roy Ladurie F Presse Med; 1992 Mar; 21(11):503-6. PubMed ID: 1315436 [No Abstract] [Full Text] [Related]